Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017;7(4):545-568.
doi: 10.3233/JPD-171203.

Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress

Camille B Carroll  1 , Richard K H Wyse  2
Affiliations
Clinical Trial

Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson's Disease: Rationale for Clinical Trial, and Current Progress

Camille B Carroll et al. J Parkinsons Dis. 2017.

Abstract

Many now believe the holy grail for the next stage of therapeutic advance surrounds the development of disease-modifying approaches aimed at intercepting the year-on-year neurodegenerative decline experienced by most patients with Parkinson's disease (PD). Based on recommendations of an international committee of experts who are currently bringing multiple, potentially disease-modifying, PD therapeutics into long-term neuroprotective PD trials, a clinical trial involving 198 patients is underway to determine whether Simvastatin provides protection against chronic neurodegeneration. Statins are widely used to reduce cardiovascular risk, and act as competitive inhibitors of HMG-CoA reductase. It is also known that statins serve as ligands for PPARα, a known arbiter for mitochondrial size and number. Statins possess multiple cholesterol-independent biochemical mechanisms of action, many of which offer neuroprotective potential (suppression of proinflammatory molecules & microglial activation, stimulation of endothelial nitric oxide synthase, inhibition of oxidative stress, attenuation of α-synuclein aggregation, modulation of adaptive immunity, and increased expression of neurotrophic factors). We describe the biochemical, physiological and pharmaceutical credentials that continue to underpin the rationale for taking Simvastatin into a disease-modifying trial in PD patients. While unrelated to the Simvastatin trial (because this conducted in patients who already have PD), we discuss conflicting epidemiological studies which variously suggest that statin use for cardiovascular prophylaxis may increase or decrease risk of developing PD. Finally, since so few disease-modifying PD trials have ever been launched (compared to those of symptomatic therapies), we discuss the rationale of the trial structure we have adopted, decisions made, and lessons learnt so far.

Keywords: Parkinson’s disease; Simvastatin; clinical trial; disease modification.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hirsch L, Jette N, Frolkis A, Steeves T, & Pringsheim T (2016) The incidence of Parkinson’s disease: A systematic review andmeta-analysis. Neuroepidemiology, 46, 292–300. - PubMed
    1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, & Tanner CM (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 30, 384–386. - PubMed
    1. Kowal SL, Dall TM, Chakrabarti R, Storm MV, & Jain A (2013) The current and projected economic burden of Parkinson’s disease in the United States. Mov Disord, 28, 311–318. - PubMed
    1. Savica R, Grossardt BR, Bower JH, Ahlskog JE, & Rocca WA (2016) Time Trends in the Incidence of Parkinson Disease. JAMA Neurol, 73, 981–989. - PMC - PubMed
    1. Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, & Siderowf AD (2013) An economic model of Parkinson’s disease: Implications for slowing progression in the United States. Mov Disord, 28, 319–326. - PubMed

Publication types

MeSH terms

Substances